Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026 May 20, 2026 08:08AM
Merck and Eisai report failed kidney cancer drug trial results Apr 21, 2026 08:37AM
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC Apr 21, 2026 06:52AM
New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer Apr 10, 2026 07:00AM
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progr Mar 27, 2026 06:14AM
View Older Stories

Mar 1, 2026 06:49PM WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Ca
Feb 26, 2026 08:08AM Eisai and Advocacy Leaders Launch "Kompass," a Digital Destination to Help Patients and Caregivers Navigate the Complexities of Kidney Cancer
Nov 3, 2025 08:08AM Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
Oct 2, 2025 08:08AM Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
May 20, 2025 08:08AM Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
Nov 26, 2024 12:50AM Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Sep 16, 2024 08:08PM LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients
Sep 4, 2024 08:08AM Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024, Including First Interim Analysis Results from the Phase 3 LEAP-012 Trial
Jun 27, 2024 04:35PM New Efficacy Data for Non-Clear Cell Renal Cell Carcinoma From KEYNOTE-B61 Added to LENVIMA® (lenvatinib) US Label Supporting KEYTRUDA + LENVIMA Indication for the First-Line Treatment of Adult Patie
Jun 27, 2024 09:35AM New Post-Hoc Analysis from Phase 3 REFLECT Trial Presented at ESMO GI 2024 Explores Efficacy Outcomes with LENVIMA® (lenvatinib) Based on Depth of Tumor Response in Unresectable Hepatocellular Carcin
May 23, 2024 08:08AM Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Jan 18, 2024 08:08AM Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024
Jan 16, 2024 08:08AM Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024
Oct 11, 2023 08:08AM Eisai to Present Research From Oncology Portfolio and Pipeline at ESMO Congress 2023
Sep 25, 2023 01:17AM "LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Aug 17, 2023 08:00AM EISAI INC.'S U.S. HEADQUARTERS EARNS THREE KEY BUILDING CERTIFICATIONS
Jul 19, 2023 09:23PM Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 19, 2023 07:30PM Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 6, 2023 08:00PM FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 11, 2023 08:13PM FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 9, 2023 06:45PM FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 7, 2023 11:32PM Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
May 23, 2023 08:08AM Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 19, 2023 08:20PM Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 15, 2023 07:27PM Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
Apr 11, 2023 08:08AM EISAI AND PATIENT ADVOCACY PARTNERS LAUNCH MADE OF MORE -- AN EDUCATION INITIATIVE TO SPOTLIGHT HEAD AND NECK CANCER
Mar 31, 2023 12:55AM Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Mar 30, 2023 07:31PM ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS
Mar 30, 2023 07:30PM EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Mar 23, 2023 08:08AM Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Mar 5, 2023 06:30PM FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Feb 27, 2023 06:30PM BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Jan 29, 2023 06:30PM LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
Jan 26, 2023 06:30PM MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY
Jan 18, 2023 08:08AM Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
Jan 15, 2023 07:30PM EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN
Jan 10, 2023 06:30PM EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE
Jan 6, 2023 11:30PM Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jan 6, 2023 02:31PM Eisai, Biogen (BIIB) Confirm FDA Approval of LEQEMBI Under Accelerated Approval Pathway for Treatment of Alzheimer's Disease
Jan 6, 2023 02:30PM FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Dec 22, 2022 06:45PM EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA
Dec 22, 2022 03:07AM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 21, 2022 08:00PM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 1, 2022 08:08AM Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
Nov 29, 2022 07:50PM ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND
Nov 29, 2022 07:50PM EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Nov 23, 2022 06:30PM EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) CIII AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
Oct 21, 2022 10:30AM Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Sep 28, 2022 07:00AM Eisai, Biogen (BIIB) Announce Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint for Reduction of Early Alzheimer's Disease
Sep 27, 2022 07:30PM LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH E
View Older Stories